Demographic and clinical characteristics of the 100 study subjects*
| Characteristics | Bromhexine (n=48) | Placebo (n=52) | P value |
| Age (years), mean (SD) | 50.7 (16.4) | 53.1 (15.2) | 0.44 |
| Male, n (%) | 22 (45.8) | 24 (46.2) | 0.97 |
| Married | 40 (83.3) | 46 (88.5) | 0.46 |
| BMI, mean (SD) | 26.2 (1.8) | 33.2 (4.5) | <0.0001 |
| Obese (BMI≥30 kg/m2), n (%) | 0 (0.0) | 47 (90.4) | <0.0001 |
| Smoker, n (%) | 4 (8.3) | 9 (17.3) | 0.18 |
| Traveled, n (%) | 7 (14.6) | 10 (19.2) | 0.54 |
| Exposure to a COVID-19 case prior to infection, n (%) | 8 (16.7) | 16 (30.8) | 0.10 |
| Blood group, n (%) | 0.91 | ||
| A+ | 10 (20.8) | 11 (21.2) | |
| A− | 1 (2.1) | 4 (7.7) | |
| B+ | 11 (22.9) | 8 (15.4) | |
| B− | 2 (4.2) | 2 (3.9) | |
| O+ | 16 (33.3) | 18 (34.6) | |
| O− | 1 (2.1) | 2 (3.9) | |
| AB+ | 4 (8.3) | 3 (5.8) | |
| AB− | 3 (6.3) | 4 (7.7) | |
| Comorbidities, n (%) | |||
| Asthma | 3 (6.3) | 3 (5.8) | 1.0 |
| Autoimmune disease | 4 (8.3) | 1 (1.9) | 0.19 |
| Cancer | 3 (6.3) | 3 (5.8) | 1.0 |
| Cerebrovascular accident | 1 (2.1) | 1 (1.9) | 1.0 |
| Chronic obstructive pulmonary disease | 3 (6.3) | 4 (7.7) | 1.0 |
| Coronary heart disease | 6 (12.5) | 3 (5.8) | 0.31 |
| Diabetes | 16 (33.3) | 17 (32.7) | 0.95 |
| Hypertension | 20 (41.7) | 19 (36.5) | 0.60 |
| Liver diagnosis | 2 (4.2) | 1 (1.9) | 0.61 |
| Renal diagnosis | 4 (8.3) | 1 (1.9) | 0.19 |
*Data are reported as mean and SD for continuous variables and number (n) and percent for categorical variables.
BMI, Body Mass Index.